Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
Clinical Trials
New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
STAND Clinical Trial Results Published
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal
TB Alliance Congratulates MSF on TB-PRACTECAL Milestone
PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study. TB-PRACTECAL is a
REMox TB Trial Paves the Way for 21st Century TB Drug Trials
In 2008, TB Alliance launched the first Phase 3 clinical trial of a new TB drug in four decades. The
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient
Building Global Capacity for Modern TB Treatment Research
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
From Drugs to Regimens: Transforming TB Drug Development
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
TB Alliance Partners with ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments against Tuberculosis
NEW YORK (January 29, 2020)—TB Alliance and partners announced the launch of the ERA4TB (European Regimen Accelerator for Tuberculosis) project